| pubmed-article:10065624 | pubmed:abstractText | Chemokines were originally isolated based on their abilities to selectively attract and recruit leukocyte populations. Over the last few years there has been an explosion in the number of new chemokines identified, and as a result many receptors previously considered to be orphans have now been paired up with their ligands. Here we review some of the latest results in this area, illustrating with data from our laboratory. The central question from a drug discovery perspective, is to show whether inhibiting chemokine receptors leads to a change in disease status. Although we are still a long way from having candidate molecules to take into the clinic, a flavour of what may be possible can be inferred from mutant chemokines with antagonistic properties. We discuss recent data using two of these proteins, Met-RANTES which has anti-inflammatory properties, and AOP-RANTES which has been shown to prevent infection of macrophages and T-cells by M-tropic HIV strains. | lld:pubmed |
